Recent Finacing
Recent Raise
Clinical-stage Enterin develops ENT-01 to displace membrane-bound α‑synuclein in enteric neurons to restore gut–brain signaling in Parkinson’s, and ENT-03 to enhance central insulin sensitivity for metabolic and neurodegenerative conditions.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
